11/29
09:06 am
pasg
Passage Bio, Inc. (NASDAQ: PASG) is now covered by analysts at Wedbush. They set an "outperform" rating and a $4.00 price target on the stock.
High
Report
Passage Bio, Inc. (NASDAQ: PASG) is now covered by analysts at Wedbush. They set an "outperform" rating and a $4.00 price target on the stock.
11/21
10:52 am
pasg
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development [Yahoo! Finance]
Low
Report
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development [Yahoo! Finance]
11/14
06:30 pm
pasg
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
High
Report
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
11/14
11:13 am
pasg
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $13.00 price target on the stock.
Low
Report
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $13.00 price target on the stock.
11/14
07:39 am
pasg
Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]
Medium
Report
Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]
11/13
07:00 am
pasg
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
High
Report
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
11/6
07:00 am
pasg
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Medium
Report
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
10/24
07:00 am
pasg
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Medium
Report
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference